Latest News

This biotech specializing in endocrine therapies reported a notable insider sale as it advances clinical-stage drug candidates.
Via The Motley Fool · March 27, 2026
Trilogy Metals and ZenaTech are two Canadian growth stocks built for 2026. Critical minerals and AI drones are driving serious upside. Here's what you need to know.
Via The Motley Fool · March 27, 2026
Analysts think Nebius, Microsoft, and Nvidia have huge upsides.
Via The Motley Fool · March 27, 2026

This spine-focused medtech firm, known for its surgical innovations, reported a notable insider sale amid ongoing portfolio expansion.
Via The Motley Fool · March 27, 2026
As stocks sell off, here's one of the Magnificent Seven stocks I think has fallen enough to make it a buy.
Via The Motley Fool · March 27, 2026
Telus (TSX:T) stock is starting to move lower again, but it is looking way too cheap as the yield swells close to 10%.
Via The Motley Fool · March 27, 2026
Why these Canadian ETFs are the top picks I'm considering for income in 2026, especially amidst the growing volatility and uncertainty.
Via The Motley Fool · March 27, 2026
It was a historic stretch of time for the biotech.
Via The Motley Fool · March 27, 2026
This investment offers a terrific combination of likely price appreciation along with dividend income.
Via The Motley Fool · March 27, 2026

This royalty-focused biotech with a broad drug portfolio reported a notable insider sale amid strong stock performance.
Via The Motley Fool · March 27, 2026
This error could really trip you up.
Via The Motley Fool · March 27, 2026
The company crushed bottom-line estimates in its final quarter of 2025.
Via The Motley Fool · March 27, 2026

This clinical-stage biotech advancing neurological therapies reported a notable insider sale as it progresses its drug pipeline.
Via The Motley Fool · March 27, 2026
Investors are concerned about restrictive regulations against social media companies.
Via The Motley Fool · March 27, 2026
Most investors hit the $109,000 TFSA milestone with consistent contributions, not one big deposit.
Via The Motley Fool · March 27, 2026
Novo Nordisk: A Strong Contender in the Pharmaceutical Arenafool.com
Could Novo Nordisk be the hidden gem you've been searching for? Join us as we evaluate its current market position and future prospects in this insightful episode.
Via The Motley Fool · March 27, 2026
The outcome for investors could be more complex than it seems.
Via The Motley Fool · March 27, 2026
The war in Iran is driving widespread selling in the stock market.
Via The Motley Fool · March 27, 2026
The performance came from an unlikely source for this company.
Via The Motley Fool · March 27, 2026
Trader barriers are increasing import prices for most businesses, including e.l.f.
Via The Motley Fool · March 27, 2026
Drivers are paying higher fuel prices.
Via The Motley Fool · March 27, 2026
Explore the strengths and use cases of AI image generators in marketing. See a four-step framework for creating efficient, crisp, and multipurpose visuals.
Via Visibility · March 26, 2026

One analyst tracking the stock shaved $10 off his price target.
Via The Motley Fool · March 27, 2026

Specializing in CNS therapies, this biopharma firm reported a notable insider sale amid a year of strong stock performance.
Via The Motley Fool · March 27, 2026
What’s the first thing that you are thinking about if you want to start your journey with trading? Chances are high that safety is among the top factors you are considering when deciding whether starting to trade is a good idea. If that sounds like you, we must congratulate you, as you have taken a [...]
Via Visibility · March 26, 2026